Estrigenix Therapeutics, Inc
October 17, 2023
Franciscan B
Oncology
Company Description: Estrigenix Therapeutics is preclinical pharmaceutical development company pioneering therapies to improving women's health. Estrigenix was formed as a spinout of collaborative research on ERbeta selective agonists at 3 Milwaukee area universities. Our focus is on a family of non-steroidal molecules for the treatment of menopause symptoms, but without the risk of breast cancer which is associated with traditional estrogen therapy. We have demonstrated the efficacy of EGX358 for moderating hot flashes and improving memory consolidation in an animal model for menopause. Furthermore EGX358 does not cause the proliferation of MCF-7 cells, the most prevalent cell line of breast cancer.
State
WI
Country
United States
Website
http://www.estrigenix.com
CEO/Top Company Official
William Donaldson
Lead Product in Development
EGX358 is a non-steroidal, small molecule which is highly selective for activation of ERbeta. It has demonstrated efficacy for moderating a chemically induced hot flash and improving memory in an animal model for menopause. Of equal importance, EGX358 does not cause the proliferation of MCF-7 breast cancer cells. As such, EGX358 exhibits the benefits of for treatment of menopause symptoms but without the risk for breast cancer which is inherent with traditional estrogen therapy.EGX358 and analogs are covered in a composition of matter patent valid through May 2035.
Development Phase of Primary Product
Pre-Clinical
Number Of Unlicensed Products
0
)
)
){kind=logo}
){kind=logo}
){kind=logo}
)
){kind=logo}
)
)